B. Riley Financial Reiterates Buy Rating for OptimizeRx (NASDAQ:OPRX)

OptimizeRx (NASDAQ:OPRX)‘s stock had its “buy” rating reissued by equities research analysts at B. Riley Financial in a research note issued on Friday,Benzinga reports. They currently have a $11.00 price objective on the stock, down from their prior price objective of $28.00. B. Riley Financial’s price objective would suggest a potential upside of 63.20% from the company’s previous close.

A number of other equities analysts have also commented on the stock. Wall Street Zen raised shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. Zacks Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Stephens cut their target price on shares of OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a research report on Friday. Citizens Jmp raised their price target on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday, December 22nd. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.57.

OptimizeRx Stock Down 10.5%

Shares of NASDAQ OPRX opened at $6.74 on Friday. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.20. The business has a 50-day moving average of $10.52 and a 200-day moving average of $14.72. The firm has a market capitalization of $125.63 million, a price-to-earnings ratio of 25.92 and a beta of 1.20. OptimizeRx has a 12 month low of $3.99 and a 12 month high of $22.25.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share for the quarter. OptimizeRx had a net margin of 4.69% and a return on equity of 10.81%. Sell-side analysts expect that OptimizeRx will post -0.33 earnings per share for the current fiscal year.

OptimizeRx declared that its board has approved a stock buyback program on Thursday, March 5th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the company to buy up to 6.8% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Institutional Investors Weigh In On OptimizeRx

Several institutional investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC grew its position in OptimizeRx by 600.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock worth $29,000 after acquiring an additional 1,818 shares during the last quarter. Hillsdale Investment Management Inc. lifted its position in OptimizeRx by 10.9% in the fourth quarter. Hillsdale Investment Management Inc. now owns 20,300 shares of the company’s stock valued at $249,000 after purchasing an additional 2,000 shares during the last quarter. Parkman Healthcare Partners LLC lifted its position in OptimizeRx by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock valued at $10,447,000 after purchasing an additional 2,188 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of OptimizeRx by 119.2% during the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares during the period. Finally, AQR Capital Management LLC grew its holdings in shares of OptimizeRx by 18.4% in the fourth quarter. AQR Capital Management LLC now owns 14,514 shares of the company’s stock worth $178,000 after purchasing an additional 2,256 shares during the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

Key OptimizeRx News

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations — OPRX reported stronger-than-expected results (EPS and revenue topped consensus), supporting the company’s underlying growth narrative. Q4 Results
• Positive Sentiment: Board authorized a $10.0M share repurchase program (up to ~6.8% of shares), a shareholder-friendly move that typically supports share price over time by reducing float. Buyback Announcement
• Neutral Sentiment: Roth MKM lowered its price target from $32 to $18 but kept a “buy” rating — still a materially higher target than current levels, creating mixed signals (cut in optimism but continued buy conviction). Roth MKM PT Change
• Neutral Sentiment: Multiple brief trading halts for OPRX were reported today due to LULD pauses — technical market safeguards that can amplify volatility but do not convey fundamental news.
• Negative Sentiment: FY2026 revenue guidance came in at $109M–$114M versus consensus near $122M — a notable shortfall that likely drove investor disappointment and downward pressure on the stock. Guidance Story
• Negative Sentiment: B. Riley reaffirmed its buy rating but cut its price target from $28 to $11 — another analyst reduction that removes prior upside and likely contributed to selling pressure. B. Riley PT Cut
• Negative Sentiment: Stephens trimmed its target to $10 and set an “equal weight” rating, signaling a more cautious view and reducing analyst-driven upside expectations. Stephens PT Change

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.